Silexion Therapeutics (NASDAQ:SLXN) Now Covered by Maxim Group

Stock analysts at Maxim Group started coverage on shares of Silexion Therapeutics (NASDAQ:SLXN) in a report released on Friday, Benzinga reports. The brokerage set a “buy” rating and a $1.00 price target on the stock. Maxim Group’s price target would suggest a potential upside of 313.22% from the stock’s previous close.

Silexion Therapeutics Stock Performance

Shares of NASDAQ SLXN opened at $0.24 on Friday. Silexion Therapeutics has a 1 year low of $0.23 and a 1 year high of $4.65. The company’s 50-day moving average is $0.67.

Silexion Therapeutics (NASDAQ:SLXN) last posted its earnings results on Thursday, August 29th. The company reported ($5.87) earnings per share for the quarter.

Silexion Therapeutics Company Profile

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor.